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Abstract
A key obstacle to creating sophisticated genetic circuits has been the lack of scalable device 
libraries. Here we present a modular transcriptional repression architecture based on clustered 
regularly interspaced palindromic repeats (CRISPR) system and examine approaches for regulated 
expression of guide RNAs in human cells. Subsequently we demonstrate that CRISPR regulatory 
devices can be layered to create functional cascaded circuits, which provide a valuable toolbox for 
engineering purposes.
Engineered biological circuits provide insights into the underlying biology of living cells 
and offer potential solutions to a range of medical and industrial challenges1, 2. A 
prerequisite for efficient engineering of such sophisticated circuits is the availability of a 
library of regulatory devices that can be connected in various contexts to create new and 
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predictable behaviors. In synthetic biology, a regulatory device is loosely defined as a set of 
biochemical regulatory interactions that implement a basic information-processing 
relationship between inputs and outputs1, 3. Here we investigate transcriptional devices 
where the input is expression of a gene product that regulates production of output from a 
corresponding promoter. In particular, we focus on repressor devices, as these can in 
principle be used to build any computational circuit, whereas activators cannot4, 5. To date, 
however, an impediment to engineering larger and more complex circuits in any living 
organism is the lack of an efficient framework for generating a sufficient number of 
composable regulatory devices (i.e., having matching input and output types and expression 
levels) that can interconnect to form functional circuits3.
Recent efforts toward developing a transcriptional framework for a large library of 
composable devices include the creation of synthetic transcriptional modifiers by fusing 
effector domains to zinc-finger proteins or transcription activator–like effector (TALE) 
proteins, albeit with limitations such as extensive DNA assembly protocols6–8 or slow 
temporal responses because of the epigenetic modifications caused by the effector domains 
at target promoters9. The Cas9 protein from the Streptococcus pyogenes CRISPR-Cas 
immune system has recently been adapted for both RNA-guided genome editing and gene 
regulation in a variety of organisms8, 10–13. This mechanism is attractive for engineering a 
large library of devices in mammalian cells because Cas9 can be targeted to virtually any 
DNA sequence by means of a small guide RNA (gRNA) and thus can be easily programmed 
for the generation of a diverse device library6. In addition, catalytically inactive Cas9 protein 
(Cas9m), not fused to any effector domains, has been shown to repress both synthetic and 
endogenous genes through steric blocking of transcription initiation and elongation8–11. 
Therefore, we decided to focus on the CRISPR system to generate synthetic gene regulatory 
devices and circuits. Specifically, we devised strategies for regulated expression of gRNAs 
in human cells using both RNA polymerase type II (RNA Pol II) and RNA Pol III 
promoters, and demonstrated that CRISPR repressor devices can be layered to create 
functional circuits with high on/off ratios.
We designed two CRISPR families of promoters regulated by Cas9m-mediated steric 
blocking of transcription: CRISPR-responsive RNA Pol II promoters (CRP; Supplementary 
Fig. 1) and CRISPR-responsive RNA Pol III U6 promoters (CR-U6; Supplementary Fig. 
2a). Both families are modular and extensible because orthogonal and highly specific 
repressor-promoter pairs can be created by altering the Cas9 target sequence and 
corresponding gRNA. Initially, we tested the ability of CRPs to regulate expression of 
enhanced YFP (EYFP) based on the presence or absence of gRNA constitutively expressed 
from a standard U6 promoter. Flow cytometry analysis 48 h after transfection of regulatory 
circuitry into human embryonic kidney 293 (HEK293) cells showed ~100-fold repression 
for two different gRNA and CRP pairs (gRNA-a and gRNA-b; Supplementary Fig. 3), and 
minimal cross-talk between the two devices, which demonstrated the desired orthogonality 
(Supplementary Fig. 4 and Supplementary Discussion). For all circuits discussed in this 
paper, one of these two CRPs regulates expression of output reporter EYFP.
An important objective for us was to investigate the potential of using CRISPR devices to 
create layered circuitry, defined as the ability to compose complex multilevel control or 
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regulatory operations by interconnecting CRISPR-based devices14. We designed the CR-U6 
architecture to both express and be regulated by gRNA, hence creating composable devices. 
We accomplished this by inserting one Cas9m target site upstream and another downstream 
of the U6 promoter TATA box, similar to the case with tetracycline-responsive U6 promoter 
variants15. We created three versions of the CRa-U6 promoter that differ in the directionality 
of gRNA-a target sites flanking the TATA box (Supplementary Fig. 2a), and our 
experiments indicate that these regulate CRP-b with comparable efficiency to the 
unmodified U6 promoter (Fig. 1a,b). We then tested composability of these three variants in 
a cascade circuit where U6-driven gRNA-a regulates CRa-U6–driven expression of gRNA-
b, which in turn regulates CRP-b expression of EYFP output (Fig. 1c). Transfection into 
HEK293 cells demonstrated highly functional layered CRISPR circuits that exhibited up to 
27-fold derepression. (Fig. 1d and Supplementary Fig. 5).
We next developed strategies for expressing gRNA from RNA Pol II promoters, specifically 
the well-studied mini-cytomegalovirus (mini-CMV) promoter, so that CRP devices can be 
likewise composed (Fig. 2). This will allow CRISPR devices to be regulated and tuned by 
commonly used modulators such as Gal4VP16 or rtTA3 (ref. 16), and to participate in the 
same framework as other protein-based regulators, sensors, actuators and reporters. We first 
inserted a gRNA sequence directly downstream of a tetracycline response element (TRE) 
promoter (Supplementary Fig. 6), a design inspired by RNA Pol II–mediated expression of 
short hairpin RNA17, 18 used for cell context–dependent expression and in vivo16, 17. Flow 
cytometry analysis 48 h after transfection of a characterization circuit with gRNA-a 
transcribed from TRE and controlling CRP-a showed substantial dose-dependent repression 
upon induction with doxycycline (Fig. 2a and Supplementary Fig. 6). Analysis of the 
reversibility of the circuit revealed an increase in EYFP expression after we removed 
doxycycline (Fig. 2c).
We also encoded gRNA as an intron with flanking splicing sequences using a strategy 
similar to that employed for intronic microRNAs12, 19(Supplementary Fig. 7). Intronic 
gRNA (igRNA) co-expressed with a protein allows additional capabilities, such as 
monitoring device regulation by observing a coexpressed fluorescent reporter. Expression of 
igRNA also potentially allows multiple gRNAs to be expressed from separate introns 
inserted in a single coding gene. Flow cytometry analysis 48 h after transfection of 
characterization circuits for both igRNA-a and igRNA-b showed substantial dose-dependent 
repression upon induction with doxycycline (Fig. 2b), as well as reversibility (Fig. 2c, 
Supplementary Figs. 8–10 and Supplementary Discussion).
To test the extensibility of CRISPR regulatory devices, we designed a small library of 
igRNA and CRP pairs that differ only in the nucleotide sequence of the designated target 
sites in the CRPs and corresponding igRNA sequences (Supplementary Fig. 11a). 
Characterization of this library showed a range of repression efficiencies from 2-fold to 30-
fold (Supplementary Fig. 11b), which suggested that we can achieve devices with varying 
regulatory properties.
We next tested whether igRNA from a CRP can regulate another CRP, forming a layered 
CRISPR cascade with connected RNA Pol-II promoters (Supplementary Fig. 12). We 
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replaced the CRa-U6 device shown in Figure 1c with CRP-a that drives expression of an 
igRNA-b as an intron of near-infrared fluorescent protein (iRFP) (Supplementary Fig. 12), 
which yielded a cascade with repression of about six fold (Fig. 2xd). A similar configuration 
of cascaded promoters (U6 followed by two CRPs) but with exchanged gRNA-a and gRNA-
b resulted in a moderately functional cascade (Supplementary Fig. 13). Circuits comprising 
only RNA Pol II promoters did not yield substantial regulation, and additional testing is 
required to address possible compositional or host-context issues related to these circuits 
(Supplementary Fig. 14)20–23.
Further analysis should directly capture the input-output behavior of our devices and 
quantify any apparent cooperativity, helping determine whether additional optimization is 
needed (e.g., more operators) for improved signal restoration to create more complex 
layered circuitry. Compared to other approaches for generating synthetic transcriptional 
regulators (e.g., TALE or zinc-finger proteins), CRISPR-based devices are likely to be better 
suited for scaling to larger and more sophisticated circuits, as the DNA required for each 
additional device is much smaller. This means that more complex circuits can be encoded 
when there are size limits on the DNA to be delivered, and that any given circuit topology 
can be encoded in a much smaller amount of DNA. Regulation by RNA interference is 
expected to integrate well with CRISPR-based devices, providing a useful means of sensing 
and effecting cell state, though at present RNA interference cannot be used on its own to 
build layered circuits. Additional scaling of the CRISPR technology and the creation of 
more complex logic may also benefit from using multiple orthogonal Cas9 proteins24. 
Finally, given the simplicity of creating additional gRNAs and corresponding promoters, 
and the high performance of the devices presented here, it should be possible to rapidly 
generate, characterize and optimize a large library of effective regulatory devices. Taken 
together, the scalability and ability to rapidly design these devices should allow CRISPR-
based circuits to facilitate a wide range of applications in human cells.
METHODS
Methods and any associated references are available in the online version of the paper.
ONLINE METHODS
Cell culture and transfection
HEK293FT cells were obtained from Invitrogen and maintained in DMEM (CellGro) 
supplemented with 10% FBS (PAA Laboratories), 1% L-glutamine–streptomycin–penicillin 
mix (CellGro) and 1% nonesential amino acids (NEAA; HyClone) at 37 °C and 5% CO2. 
rtTA3 stable cell lines (HEK293-rtTA3) were created by lentiviral transduction of HEK293 
cells with rtTA3 coding sequence under a constitutive promoter and antibiotic selection with 
hygromycin for 2 weeks. All experiments were done in HEK293-rtTA3 cell lines. 
Transfections were performed using Attractene reagent (QIAGEN). Cells were seeded the 
day before at 2 × 105 cells per well in a 24-well plate. Dosages of plasmids used for the 
transfections were identified after optimization experiments for each component of the 
devices and circuits (data not shown). For transfections involving the repression devices, 
500 ng of input gRNA plasmid was mixed with a cocktail of other plasmids (ratio of 1x:4x:
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14x:4x for Gal4VP16-2A-rtTa3 plasmid, EYFP (output) expression plasmid, Cas9m-BFP 
expression plasmid and mKate expression plasmid, respectively, where x = 5 ng) in 70 µl of 
DMEM (without supplements). For transfection of the cascade circuits of two U6-based 
devices, 500 ng of the stage 1 gRNA–encoding plasmid was mixed with a cocktail of other 
plasmids (ratio of 2x:x:14x:10x:5x for Gal4VP16-2A-rtta3 plasmid, EYFP (output) 
expression plasmid, Cas9m-BFP expression plasmid, stage 2 gRNA plasmid and mKate 
expression plasmid, respectively, where x = 5 ng). For transfections of the cascade circuits 
of other devices the concentration of the stage 2 gRNA encoding plasmid was twice the 
value of stage 2 gRNA in U6-only cascades. In control experiments, we replaced the DNA 
plasmid under study with an equivalent amount of empty DNA plasmid to maintain the total 
amount of transfected DNA constant among the groups. 1.5 µl of Attractene was added to 
DNA mixtures, and the tube was gently mixed and kept at room temperature for 20 min to 
form the DNA-liposome complex. Fresh medium was added to the cells directly before 
transfection (500 µl of DMEM with supplements). The DNA-Attractene solution was then 
added drop-wise to the wells. Induction of the circuit was performed at this time as well by 
addition of doxycycline. In experiments involving the cascade, the ratio of stage 1 gRNA 
encoding plasmid to the stage 2 gRNA encoding plasmid was 5:1, except for U6-only 
cascades in which the ratio was 10:1.
Plasmids
Plasmids used for this project were constructed using the Gateway system (Invitrogen). A 
plasmid encoding catalytically mutant Cas9 fused to BFP was obtained from Addgene 
(plasmid 46910). The expression vectors were made by Gateway cloning. The U6-driven 
gRNA expression cassettes were ordered as gblocks from IDT and cloned into a pCR2.1-
TOPO TA vector by Topo TA cloning. The library of CRPs were ordered as gene fragments 
from IDT and assembled into an appropriate promoter entry vector. igRNA library elements 
were also ordered as gblocks from IDT and assembled into the mKate entry vector by 
appropriate restriction digest. Sequences are available in the Supplementary Note.
Flow cytometry
Flow cytometry data were collected 48 h after transfection. Cells were trypsinized and 
centrifuged at 453 g for 5 min at 4 °C. The supernatant was then removed, and the cells were 
resuspended in Hank’s Balanced Salt Solution without calcium or magnesium supplemented 
with 2.5% FBS. BD LSRII was used to obtain flow cytometry measurements with the 
following settings: EBFP, measured with a 405 nm laser and a 450/50 filter; EYFP, 
measured with a 488 nm laser and a 530/30 filter; mKate, measured with a 561 nm laser and 
a 695/40 filter. At least 100,000 events were gathered from each sample, ensuring that any 
1/10 decade interval with more than 5% of the mean density of events would contain at least 
100 expected events.
Statistical analysis
Flow cytometry data were converted from arbitrary units to compensated molecules of 
equivalent fluorescein (MEFL) using the Tool-Chain to Accelerate Synthetic Biological 
Engineering (TASBE) characterization method (MIT CSAIL Tech. Report 2012–008 (2012). 
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An affine compensation matrix is computed from single positive and blank controls. FITC 
measurements are calibrated to MEFL using SpheroTech RCP-30-5-A beads, and mappings 
from other channels to equivalent FITC are computed from DNA co-transfection of 
constitutive EBFP, EYFP and mKate (plus iRFP, for four-color experiments) each 
controlled by the Hef1a promoter on its own otherwise identical plasmid. nontransfected 
controls were included in each experiment. MEFL data are segmented by constitutive 
fluorescent protein expression into logarithmic bins at 10 bins per decade, and geometric 
mean and variance are computed for those data points in each bin. Based on the observed 
constitutive fluorescence distributions (Supplementary Fig. 15), a threshold was selected as 
a cutoff for each data set, below which data were excluded as being too close to the non-
transfected population. Data shown in the figures are geometric mean and s.d. of means for 
cells expressing the transfection marker mKate based on the MEFL threshold set. High 
outliers were removed by excluding all bins without at least 100 data points. Both 
population and per-bin geometric statistics were computed over this filtered set of data. 
Sample sizes were pre-determined for each experiment. During analysis of flow cytometry 
data, samples were excluded by the following predetermined criteria: if they contained less 
than 10% of the number of events or less than 10% of the fraction of successful transfections 
of the mode for the batch in which they were collected.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
This work was supported by US National Institutes of Health grants 5R01CA155320-04 and P50 GM098792. We 
thank L. Wrobleska and P. Guye (Massachusetts Institute of Technology) for providing the initial intronic miRNA–
based plasmid and the primary Cas9 construct, and for helpful discussions, and M. Graziano (Massachusetts 
Institute of Technology) for providing us the HEK293 cell lines that constitutively express rtTA3. J.H. was partially 
supported by the Intelligent Synthetic Biology Center of Global Frontier Project (2013M3A6A8073557) funded by 
the Ministry of Science, Information and Communication Technology (ICT) and Future Planning of Korea.
References
1. Andrianantoandro E, Basu S, Karig DK, Weiss R. Mol. Systems Biology. 2006; 2:0028.
2. Ruder WC, Lu T, Collins JJ. Science. 2011; 333:1248–1252. [PubMed: 21885773] 
3. Slusarczyk AL, Lin A, Weiss R. Nat. Rev. Genet. 2012; 13:406–420. [PubMed: 22596318] 
4. Bird, J. Engineering Mathematics. Vol. 532. Elsevier Science; 2007. 
5. Peirce, CS. Collected Papers of Charles Sanders Peirce. Vol. 4. Harvard University Press; 1933. p. 
12-20.
6. Farzadfard F, Perli SD, Lu TK. ACS Synthetic Biol. 2013; 2:604–613.
7. Khalil AS, et al. Cell. 2012; 150:647–658. [PubMed: 22863014] 
8. Garg A, et al. Nucleic Acids Res. 2012; 40:7584–7595. [PubMed: 22581776] 
9. Kramer BP, Fischer C, Fussenegger M. Biotechnol. Bioeng. 2004; 87:478–484. [PubMed: 
15286985] 
10. Stanton BC, et al. Nat. Chem. Biol. 2014; 10:99–105. [PubMed: 24316737] 
11. Fu Y, et al. Nat. Biotechnol. 2013; 31:822–826. [PubMed: 23792628] 
12. Mali P, et al. Science. 2013; 339:823–826. [PubMed: 23287722] 
13. Qi LS, et al. Cell. 2013; 152:1173–1183. [PubMed: 23452860] 
Kiani et al. Page 6













14. Nielsen AA, Segall-Shapiro TH, Voigt CA. Curr. Opin. Chem. Biol. 2013; 17:878–892. [PubMed: 
24268307] 
15. Henriksen JR, et al. Nucleic Acids Res. 2007; 35:e67. [PubMed: 17426119] 
16. Ko JK, Choi KH, Zhao X, et al. FASEB J. 2011; 25:2638–2649. [PubMed: 21518849] 
17. Xia H, et al. Nat. Biotechnol. 2002; 20:1006–1010. [PubMed: 12244328] 
18. Giering JC, Grimm D, Storm TA, Kay MA. Molecular therapy. 2008; 16:1630–1636. [PubMed: 
18665161] 
19. Lin SL, et al. Biochem. Biophys. Res. Commun. 2003; 310:754–760. [PubMed: 14550267] 
20. Cardinale S, Arkin AP. Biotechnol. J. 2012; 7:856–866. [PubMed: 22649052] 
21. Gyorgy A, Del Vecchio D. PLoS Comp. Biol. 2014; 10
22. Dennis PP, Ehrenberg M, Bremer H. Microbiol. Mol. Biol. Rev. 2004; 68:639–668. [PubMed: 
15590778] 
23. Klumpp S, Hwa T. Proc. Natl. Acad. Sci. USA. 2008; 105:20245–20250. [PubMed: 19073937] 
24. Esvelt KM, et al. Nat. Methods. 2013; 10:1116–1121. [PubMed: 24076762] 
Kiani et al. Page 7














Design and experimental analysis in human cells of CRISPR repression devices and circuits 
based on the RNA Pol III U6 promoter. (a) Schematic of CRP repression device. CRa-U6 
drives expression of gRNA-b, which in turn regulates EYFP output. (b) Flow cytometry–
based analysis of three repression devices based on CRa-U6–driven gRNA-b expression, in 
HEK293 cells transfected with the indicated CRa-U6 promoter variants (V1–V3). Shown is 
geometric mean and s.d. of means of molecules of equivalent fluorescein (MEFL) of EYFP 
for cells expressing >3 × 106 MEFL of transfection marker mKate. n = 4 independent 
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technical replicates, combined from two experiments. (c) Schematic of CRISPR 
transcriptional repression device cascade. U6-driven gRNA-a regulates CRa-U6–driven 
expression of gRNA-b, which in turn regulates CRP-b expression of output EYFP. (d) 
EYFP fluorescence for samples transfected either with all transcriptional units (+ for stage 1; 
V1 or V2 or V3 for stage 2), with all units but without U6-driven gRNA-a (– for stage 1) 
and with all units but without CRa-U6–driven gRNA-b (+ for stage 1; – for stage 2). Data 
represent geometric mean and s.d. of means of EYFP MEFL for cells expressing >1 × 107 
MEFL of transfection marker mKate for n = 4 biological replicates pooled from two 
representative experiments.
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Design and experimental analysis in human cells of CRISPR repression devices and circuits 
based on RNA Pol II promoters. (a) Schematic of a gRNA-a repression device regulated by 
TRE promoter and inducible by doxycycline (Dox) (top). EYFP output fluorescence was 
measured for samples transfected with or without Cas9m vector and TRE-driven gRNA-a 
with indicated amounts of Dox (top). Shown are geometric mean and s.d. of means of 
molecules of equivalent fluorescein (MEFL) of EYFP for cells expressing >106 MEFL of 
transfection marker mKate. n = 3 independent technical replicates combined from three 
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experiments. (b) Schematic of igRNA repression devices expressing mKate and igRNA 
regulated by TRE promoter. EYFP fluorescence was measured for samples transfected with 
circuits containing igRNA-a or igRNA-b devices under indicated amounts of Dox. 
Geometric mean and s.d. of means of EYFP MEFL for cells expressing >106 MEFL of 
transfection marker mKate. n=2 (gRNA-a) and 3 (gRNA-b) independent technical replicates 
combined from two and three experiments, respectively. (c) Analysis of reversible 
repression: TRE–gRNA-a circuit from a (top) and TRE/mKate-igRNA-b circuit from b 
(bottom). Two phases, where in each phase “ON” indicates induction with 4 mM Dox, and 
“OFF” indicates zero Dox. Initial phase is 24 h (top) or 12 h (bottom) after transfection. 
Experimental results are reported for the second phase that includes indicated modulations 
of Dox. Reversibility is shown by comparison between the different groups. Geometric 
mean and s.d. of EYFP MEFL means for cells expressing >106 MEFL of Cas9m-BFP. n = 2 
independent technical replicates combined from two experiments. (d) Schematic of cascades 
with igRNA (top). EYFP output fluorescence for samples transfected with or without U6–
gRNA-a (stage 1) and CRP-a–igRNA-b (stage 2) (bottom). Geometric mean and s.d. of 
EYFP means for cells expressing >3 × 106 MEFL. n = 4 independent technical replicates 
combined from two experiments.
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